# An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

> **NCT02186769** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Risperdal® Consta®
- **DRUG:** LY03004

## Key facts

- **NCT ID:** NCT02186769
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02186769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02186769, "An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02186769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*